Journal Watch · Frontiers in Immunology · 2026

Subsequent treatment strategies following rituximab-resistance in AQP4-IgG+ neuromyelitis optica spectrum disorder: a case series.

These real-world observations provide hypothesis-generating data that may inform clinical decision-making and warrant validation in larger, prospective cohorts.

Deng M, Chen L, Chen W et al.Frontiers in Immunology3 min readPharma relevance 85/100

DOI: 10.3389/fimmu.2026.1762535PMID: 42079607Study type: cohort / observational clinical study

TL;DR

These real-world observations provide hypothesis-generating data that may inform clinical decision-making and warrant validation in larger, prospective cohorts.

Key findings

  • These real-world observations provide hypothesis-generating data that may inform clinical decision-making and warrant validation in larger, prospective cohorts.

Numbers at a glance (from the abstract)

75%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

In contrast, the patient who switched to ofatumumab experienced relapse, and three of the four patients (75%) on de-escalations had at least one relapse. No significant adverse events occurred in patients treated with ofatumumab, inebilizumab, satralizumab, or eculizumab, while two serious adverse events were reported among those on de-escalation regimens.<h4>Conclusion</h4>In this descriptive case series of 10 patients with RTX-resistant NMOSD, those who switched to inebilizumab, satralizumab, or eculizumab appeared to have fewer relapses and a favorable safety profile compared to those receiving de-escalation strategies or ofatumumab.

Full abstract (original)

Background: <h4>Objective</h4>This case series describes alternative treatments for adults with aquaporin 4 immunoglobulin G-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who exhibited disease activity despite having sustained B cell depletion for more than six months post-rituximab (RTX), a condition we defined as RTX resistance.<h4>Methods</h4>We conducted a single-center, retrospective case series of 10 AQP4-IgG-positive NMOSD patients who met our definition of RTX resistance and subsequently switched therapies. Among the 10 patients, one was switched to the anti-CD20 monoclonal antibody ofatumumab, two to the anti-CD19 monoclonal antibody inebilizumab, two to the IL-6 receptor antagonist satralizumab, and one to the C5 complement inhibitor eculizumab, while 4 transitioned to de-escalations (mycophenolate mofetil, intravenous immunoglobulin, or steroids).<h4>Results</h4>Over a median follow-up of 28.4 months after treatment switch, no relapses were observed among patients who received inebilizumab, satralizumab, or eculizumab.

What they did: In contrast, the patient who switched to ofatumumab experienced relapse, and three of the four patients (75%) on de-escalations had at least one relapse. No significant adverse events occurred in patients treated with ofatumumab, inebilizumab, satralizumab, or eculizumab, while two serious adverse events were reported among those on de-escalation regimens.<h4>Conclusion</h4>In this descriptive case series of 10 patients with RTX-resistant NMOSD, those who switched to inebilizumab, satralizumab, or eculizumab appeared to have fewer relapses and a favorable safety profile compared to those receiving de-escalation strategies or ofatumumab.

Results & conclusions: These real-world observations provide hypothesis-generating data that may inform clinical decision-making and warrant validation in larger, prospective cohorts.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1762535 · PubMed 42079607.

Why it matters for pharma & biotech

  • Directly relevant to teams in antibody / ADC therapeutics, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: antibody / ADC therapeutics · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

These real-world observations provide hypothesis-generating data that may inform clinical decision-making and warrant validation in larger, prospective cohorts.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. In contrast, the patient who switched to ofatumumab experienced relapse, and three of the four patients (75%) on de-escalations had at least one relapse.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1762535. PubMed ID: 42079607. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Deng M, Chen L, Chen W et al.. Subsequent treatment strategies following rituximab-resistance in AQP4-IgG+ neuromyelitis optica spectrum disorder: a case series.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1762535.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/subsequent-treatment-strategies-following-rituximab-resistance-in-aqp4-i-762535/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides